LON:DXRX Diaceutics (DXRX) Share Price, News & Analysis GBX 150 +3.50 (+2.39%) As of 09/4/2026 11:47 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and Trends About Diaceutics Stock (LON:DXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Diaceutics alerts:Sign Up Key Stats Today's Range 147.56▼ 15050-Day Range 127▼ 154.9652-Week Range 125▼ 180Volume37,062 shsAverage Volume201,732 shsMarket Capitalization£126.94 millionP/E Ratio1,363.64Dividend YieldN/APrice TargetGBX 215Consensus RatingBuy Company Overview At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®. Read More Diaceutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreDXRX MarketRank™: Diaceutics scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingDiaceutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialDiaceutics has a consensus price target of GBX 215, representing about 43.3% upside from its current price of GBX 150.Amount of Analyst CoverageDiaceutics has only been the subject of 1 research reports in the past 90 days.Read more about Diaceutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Diaceutics is 1,363.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 45.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Diaceutics is 1,363.64, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.54.Price to Book Value per Share RatioDiaceutics has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for DXRX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDiaceutics does not currently pay a dividend.Dividend GrowthDiaceutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News SentimentN/A News SentimentDiaceutics has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Diaceutics this week, compared to 0 articles on an average week. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Diaceutics insiders have not sold or bought any company stock.Percentage Held by Insiders26.33% of the stock of Diaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions32.64% of the stock of Diaceutics is held by institutions.Read more about Diaceutics' insider trading history. Receive DXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DXRX Stock News HeadlinesDiaceutics issues new shares under incentive plans, updates total voting rightsSeptember 2, 2026 | tipranks.comDiaceutics and PCC Launch NGS Study to Boost Confidence in Cancer DiagnosticsAugust 20, 2026 | tipranks.comWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades near 4,500 dollars today, a 113-to-1 gap between book value and market reality. Treasury Secretary Scott Bessent has said he wants to monetize the asset side of the balance sheet. A revaluation could add more than 1 trillion dollars to the government's books overnight. Certain gold miners still trade as if gold were under 2,000 dollars, even as prices near record highs. | Golden Portfolio (Ad)Diaceutics boosts employee share incentives and updates total voting rightsAugust 4, 2026 | tipranks.comDiaceutics Issues Shares Under Employee Incentive Schemes in Latest Block Listing UpdateApril 7, 2026 | tipranks.comDiaceutics Executes Routine Management Share Purchases Under Incentive Plan With No Change to Share CapitalApril 1, 2026 | tipranks.comDiaceutics Issues New Shares to Trust as PDMRs Participate in Incentive PlanFebruary 3, 2026 | tipranks.comDiaceutics PLC Expands Employee Share Incentive PlanNovember 28, 2025 | tipranks.comSee More Headlines DXRX Stock Analysis - Frequently Asked Questions How have DXRX shares performed this year? Diaceutics' stock was trading at GBX 128 at the start of the year. Since then, DXRX shares have increased by 17.2% and is now trading at GBX 150. How were Diaceutics' earnings last quarter? Diaceutics PLC (LON:DXRX) issued its quarterly earnings data on Tuesday, May, 26th. The company reported $11.00 earnings per share for the quarter. The company had revenue of $38.44 million for the quarter. Diaceutics had a net margin of 0.25% and a trailing twelve-month return on equity of 0.25%. How do I buy shares of Diaceutics? Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Diaceutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR). Company Calendar Last Earnings5/26/2026Today9/06/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolLON:DXRX CIKN/A Webwww.diaceutics.com PhoneN/AFaxN/AEmployees151Year FoundedN/APrice Target and Rating Average Price Target for DiaceuticsGBX 215 High Price TargetGBX 215 Low Price TargetGBX 215 Potential Upside/Downside+43.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)GBX 0.11 Trailing P/E Ratio1,363.64 Forward P/E Ratio148.40 P/E GrowthN/ANet Income-£2.84 million Net Margins0.25% Pretax MarginN/A Return on Equity0.25% Return on Assets-6.06% Debt Debt-to-Equity Ratio2.85 Current Ratio3.43 Quick Ratio9.92 Sales & Book Value Annual Sales£38.44 million Price / Sales3.30 Cash FlowGBX 48.08 per share Price / Cash Flow3.12 Book ValueGBX 45.87 per share Price / Book3.27Miscellaneous Outstanding Shares84,629,000Free FloatN/AMarket Cap£126.94 million OptionableNot Optionable Beta0.89 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (LON:DXRX) was last updated on 9/6/2026 by MarketBeat.com Staff. From Our PartnersThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe trapdoor has a date on itRepublicans hold the House 220 to 215. Just three seats could flip control, and more than 35 GOP members have ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diaceutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Diaceutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
